US20130109745A1 - Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients - Google Patents
Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients Download PDFInfo
- Publication number
- US20130109745A1 US20130109745A1 US13/809,752 US201113809752A US2013109745A1 US 20130109745 A1 US20130109745 A1 US 20130109745A1 US 201113809752 A US201113809752 A US 201113809752A US 2013109745 A1 US2013109745 A1 US 2013109745A1
- Authority
- US
- United States
- Prior art keywords
- macrolactin
- diseases
- angiogenesis
- composition according
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ATDNANWCYCSPTL-ZJTGEQBASA-N *.*.*.*.*.*.C.C.C.C.C.C.CC1CCC/C=C/C=C/[C@H](O)C[C@@H](O)C/C=C\C=C\[C@@H](O)C/C=C/C=C\C(=O)O1.CC1CCC/C=C/C=C/[C@H](O)C[C@@H](O)C/C=C\C=C\[C@@H](OC(=O)CC(=O)O)C/C=C/C=C\C(=O)O1.CC1CCC/C=C/C=C/[C@H](O)C[C@@H](O)C/C=C\C=C\[C@@H](OC(=O)CCC(=O)O)C/C=C/C=C\C(=O)O1.S.S.S.S.S.S Chemical compound *.*.*.*.*.*.C.C.C.C.C.C.CC1CCC/C=C/C=C/[C@H](O)C[C@@H](O)C/C=C\C=C\[C@@H](O)C/C=C/C=C\C(=O)O1.CC1CCC/C=C/C=C/[C@H](O)C[C@@H](O)C/C=C\C=C\[C@@H](OC(=O)CC(=O)O)C/C=C/C=C\C(=O)O1.CC1CCC/C=C/C=C/[C@H](O)C[C@@H](O)C/C=C\C=C\[C@@H](OC(=O)CCC(=O)O)C/C=C/C=C\C(=O)O1.S.S.S.S.S.S ATDNANWCYCSPTL-ZJTGEQBASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention relates to an anti-angiogenic composition containing macrolactin compounds having anti-angiogenic activity, such as macrolactin A (MA), 7-O-malonyl macrolactin A (MMA), and 7-O-succinyl macrolactin A (SMA) as active ingredients.
- macrolactin A MA
- MMA 7-O-malonyl macrolactin A
- SMA 7-O-succinyl macrolactin A
- a pharmaceutical composition for preventing or treating diseases caused by angiogenesis is provided by using the anti-angiogenic composition according to the present invention.
- Angiogenesis is a process wherein a new capillary is generated from an existing microvessel. Normal angiogenesis occurs in embryonic development, tissue regeneration and wound treatment, and luteinization—a periodic change in the female reproductive system—and it proceeds under strict control (Folkman J. et al., Int. Rev. Exp. Pathol., 16, pp. 207-248, 1976).
- Vascular endothelial cells grow very slowly in adults and are rarely divided compared with other types of cells.
- the process of angiogenesis progresses with decomposition of the basal membrane of blood vessels by protease due to the stimulation of angiogenesis-stimulating factor, migration and proliferation of vascular endothelial cells, and tubular formation due to differentiation of vascular endothelial cells, which results in reconstruction of blood vessels to form a new capillary.
- Angiogenesis-related diseases occurring in pathological conditions include angioma, angiofibroma, vascular malformations, cardiovascular diseases such as atherosclerosis, vascular adhesion, scleredema and ophthalmic diseases such as keratoplastic angiogenesis, neovascular glaucoma, diabetic retinopathy, neovascular corneal diseases, spot degenerations, pterygium, retinal degeneration, retrolental fibroplasia and granular conjunctivitis.
- Chronic inflammatory diseases such as arthritis, skin diseases such as psoriasis, telangiectasis, pyogenic granuloma, seborrheic dermatitis and acne, Alzheimer's and obesity are also related to angiogenesis. Furthermore, growth and metastasis of cancer are necessarily dependent on angiogenesis (D'Amato R. J. et al., Ophthalmology, 102(9), pp. 1261-1262, 1995; Arbiser J. L., J. Am. Acad. Dermatol., 34(3), pp. 486-497, 1996; O'Brien K. D. et al. Circulation, 93(4), pp. 672-682, 1996; Hanahan D. et al., Cell, 86, pp. 353-364, 1996).
- angiogenesis plays an important role in the growth and metastasis of cancer cells.
- Tumors are provided with nutrients and oxygen by new blood vessels, which infiltrate the tumors and give cancer cells an opportunity to enter into blood circulation to aid metastasis of cancer (Folkman and Tyler, Cancer Invasion and Metastasis , Biological Mechanism and Therapy (S. B. Day, ed.) Raven Press, New York, pp. 94-103, 1977; Polverini P. J., Crit. Rev. Oral. Biol. Med. 6(3), pp. 230-247, 1995).
- a principal reason that chemotherapies or immunotherapies for cancer patients scarcely contribute to increasing the survival rates of patients is metastasis of cancer.
- Arthritis a typical inflammatory disease, is primarily induced by an autoimmune disorder. As the disease progresses, chronic inflammation in synovial bursa between the joints induces angiogenesis and destroys cartilage. That is, synovial cells and vascular endothelial cells proliferate with the aid of inflammation-inducing cytokine, and as angiogenesis progresses, joint pannus, which is connective tissue layer generated in cartilage, is formed to destroy the cushioning cartilage (Koch A. E. et al., Arthritis. Rheum., 29, pp. 471-479, 1986; Stupack D. G. et al., Braz, J. Med. Biol. Res., 32(5), pp. 578-581, 1999; Koch A. E., Arthritis Rheum., 41(6), pp. 951-962, 1998).
- Ophthalmic diseases which make millions of people blind every year, result from angiogenesis (Jeffrey M. I. et al., J. Clin. Invest., 103, pp. 1231-1236, 1999).
- macular degeneration occurring in the aged, diabetic retinopathy, retinopathy of a precocious child, neovascular glaucoma and neovascular corneal diseases are caused by angiogenesis (Adamis A. P. et al., Angiogenesis, 3, pp. 9-14, 1999).
- diabetic retinopathy is a complication of diabetes which results in blindness due to the invasion of retinal capillaries into the vitreous body.
- Psoriasis characterized by red spot and scaled skin, is a chronic proliferative disease occurring in skin that is difficult to treat, and involves pain and deformation. While in a normal state keratin cells proliferate once a month, in psoriasis patients they proliferate once a week. For such rapid proliferation, profuse blood must be provided, which forces active angiogenesis (Folkman J., J. Invest. Dermatol., 59, pp. 40-48, 1972).
- Anti-angiogenic agents can be applied to treat various angiogenic diseases. Since anti-angiogenic agents are generally administered to patients for a long time, those of low toxicity and which are orally administered are ideal. Thus, there is a great need to develop a novel anti-angiogenic agent with low toxicity.
- Macrolactin compounds are produced from unclassified ocean bacteria, actinomyces and Bacillus strains (Willam Fenical et al., J. Am. Chem. Soc., 111, pp. 7519-7524, 1989; Ik Dong Yoo et al., J. Microbiol. Biotechnol., 7, pp. 429-434, 1997; Gabriella Molinari et al., Antimicrob. Agents Chemother., 50, pp. 1701-1709, 2006), and 23 macrolactin compounds have been identified. Prior studies on the pharmacological activities of the macrolactin compounds are as follows.
- MA isolated for the first time in 1989, suppresses the proliferation of murine melanoma cancer cell and Herpes simplex virus, and protects T-lymphoblast damaged by HIV (Willam Fenical et al., J. Am. Chem. Soc., 111, pp. 7519-7524, 1989). Furthermore, it suppresses squalene synthase (Sung Won Choi et al., Can. J. Microbiol., 49, pp. 663-668, 2003), protects brain cells damaged by glutamate (Ik Dong Yoo et al., J. Microbiol. Biotechnol., 7, pp.
- the present inventors confirmed that MA, MMA and SMA were produced from Bacillus polyfermenticus KJS-2 (KCCM10769P, hereinafter, “BP2”) fermentation or culture medium and identified their structures. Besides the three macrolactin compounds, the present inventors also confirmed by LC/Mass that macrolactin B, macrolactin C, macrolactin D, macrolactin E, macrolactin F, macrolactin G, macrolactin H, macrolactin I, macrolactin J, macrolactin K, macrolactin L, macrolactin M, macrolactin N, isomacrolactinic acid and macrolactinic acid were produced from the BP2 fermentation or culture medium crude extract (Korean Patent No. 10-0895908). However, the present inventors did not confirm the production of macrolactin O, macrolactin P, macrolactin Q, macrolactin R or macrolactin S from BP2.
- BP2 Bacillus polyfermenticus KJS-2
- Macrolactin compounds have various pharmacological activities for their various structures.
- studies about the anti-angiogenesis of macrolactin compounds have never been reported until now.
- the present inventors fractionated the crude extract produced from the BP2 fermentation or culture medium including various macrolactin compounds using middle-pressure liquid chromatography (MPLC) and investigated anti-angiogenic activity of each fraction to find that the fractions containing macrolactin compounds suppress angiogenesis, and especially, the fractions containing MA, MMA and SMA strongly suppress angiogenesis.
- MPLC middle-pressure liquid chromatography
- the present inventors highly purified each compound from the MPLC fractions containing the three macrolactin compounds (PCT/KR2010/003239) and investigated the anti-angiogenic activity of each purified macrolactin compound.
- the object of the present invention is to provide a pharmaceutical composition comprising the macrolactin compounds as active for preventing or treating diseases caused by angiogenesis.
- the present invention provides an anti-angiogenic composition comprising at least one of the compounds of Formula 1, Formula 2 and Formula 3 as active ingredients.
- the present invention provides a pharmaceutical composition comprising at least one of the compounds of Formula 1, Formula 2 and Formula 3 as active ingredients for preventing or treating angiogenesis-related diseases.
- angiogenesis-related diseases rheumatoid arthritis, osteoarthritis, septic arthritis, psoriasis, corneal ulcer, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, immature retinopathy, ophthalmic inflammation, conical cornea, Sjogren's syndrome, myopia ophthalmic tumor, rejection of corneal transplantation, abnormal cut conglutination, bone disease, proteinuria, disorders of abdominal aneurysm, cartilage loss resulting from traumatic joint damage, neurologic demyelination, cirrhosis, glomerular diseases, immature rupture of embryo-fetal membrane, inflammatory bowel diseases, periodontal diseases, arteriosclerosis, restenosis, inflammatory diseases of the central nervous system, Alzheimer's disease, skin aging, infiltration and metastasis of cancer, etc. are known.
- the macrolactin compounds of the present invention can be obtained by the preparation method disclosed in the patent application (PCT/KR2010/003239) which is owned by the present inventors.
- MA, MMA and SMA which correspond to the compounds of Formula 1, Formula 2 and Formula 3, respectively, are obtained by the processes of fermentation using Bacillus polyfermenticus KJS-2 (KCCM10769P) which is isolated by the present inventors, extraction, separation and purification.
- the compounds of the present invention obtained from the above method strongly suppressed neovascular formation and metastasis of cancer caused by angiogenesis which were induced by the treatment of angiogenic inducers such as vascular endothelial growth factor (VEGF), tumor necrosis factor- ⁇ (TNF- ⁇ ,) and interleukin-8 (IL-8) in in vivo tests using a chicken chorio-allantoic membrane model; thereby it is confirmed that the compounds can be used as a pharmaceutical composition for preventing and treating angiogenesis-related diseases.
- VEGF vascular endothelial growth factor
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-8 interleukin-8
- MA, MMA and SMA provided by the present invention strongly suppressed neovascular formation in in vivo tests using a chicken chorio-allantoic membrane model, and therefore the pharmaceutical composition comprising them as active ingredients can be used for preventing and treating diseases caused by angiogenesis.
- FIG. 1 a is composed of photographs of a stereomicroscope for the chorio-allantoic membrane in the Examples showing the suppressive effect of the compounds according to the present invention on neovascular formation induced by VEGF.
- FIG. 1 b is a graph showing the suppressive effect of the compounds according to the present invention on neovascular formation induced by VEGF.
- FIG. 2 a is composed of photographs of a stereomicroscope for the chorio-allantoic membrane in the Examples showing the suppressive effect of the compounds according to the present invention on neovascular formation induced by TNF- ⁇ .
- FIG. 2 b is a graph showing the suppressive effect of the compounds according to the present invention on neovascular formation induced by TNF- ⁇ .
- FIG. 3 a is composed of photographs of a stereomicroscope for the chorio-allantoic membrane in the Examples showing the suppressive effect of the compounds according to the present invention on neovascular formation induced by IL-8.
- FIG. 3 b is a graph showing the suppressive effect of the compounds according to the present invention on neovascular formation induced by IL-8.
- FIG. 4 a is composied of photographs showing the suppressive effect of the compounds according to the present invention on metastasis of fibrosarcoma cells induced by 5% FBS.
- FIG. 4 b is a graph showing the suppressive effect of the compounds according to the present invention on metastasis of fibrosarcoma cells induced by 5% FBS.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising MA, MMA or SMA as active ingredients and pharmaceutically acceptable carriers or excipients for preventing or treating diseases caused by angiogenesis.
- the diseases caused by angiogenesis are at least one selected from the group consisting of rheumatoid arthritis, osteoarthritis, septic arthritis, psoriasis, corneal ulcer, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, immature retinopathy, ophthalmic inflammation, conical cornea, Sjogren's syndrome, myopia ophthalmic tumor, rejection of corneal transplantation, abnormal cut conglutination, bone disease, proteinuria, disorders of abdominal aneurysm, cartilage loss resulting from traumatic joint damage, neurologic demyelination, cirrhosis, glomerular diseases, immature rupture of embryo-fetal membrane, inflammatory bowel diseases, periodontal diseases, arteriosclerosis, restenosis, inflammatory diseases of the central nervous system, Alzheimer's disease, skin aging, and infiltration and metastasis of cancer.
- the above pharmaceutical composition comprises at least one of MA, MMA and SMA, which are macrolactin compounds produced from the culture medium or fermentation medium of Bacillus polyfermenticus strains including BP2, as active ingredients and pharmaceutically acceptable carriers or excipients.
- MA macrolactin compounds produced from the culture medium or fermentation medium of Bacillus polyfermenticus strains including BP2, as active ingredients and pharmaceutically acceptable carriers or excipients.
- the pharmaceutical composition of the present invention for preventing or treating angiogenesis-related diseases can further include suitable carriers, excipients or diluents conventionally used in manufacturing pharmaceutical compositions.
- Examples of the carriers, excipients or diluents which can be included in the pharmaceutical composition of the present invention for preventing or treating angiogenesis-related diseases are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, potassium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxyl benzoate, propyl hydroxyl benzoate, talc, magnesium stearate and mineral oil.
- the pharmaceutical composition according to the present invention comprising at least one of MA, MMA and SMA can be formulated as oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories, instillations, eardrops and sterilized injections using conventional preparation methods.
- the preparations are formulated by means of conventionally used diluents or excipients such as fillers, extenders, binders, humectants, disintegrating agents and surfactants.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and they are formulated by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose and gelatin.
- lubricants such as magnesium stearate and talc are used.
- Liquid preparations for oral administration are suspensions, gel solutions, emulsions, syrups, etc.
- liquid preparations In addition to the conventionally used simple diluents such as water and liquid paraffin, various excipients such as humectants, sweetening agents, flavoring agents and preservatives can be included in the liquid preparations.
- Preparations for parenteral administration include sterilized gel solutions, nonaqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, instillations and eardrops.
- nonaqueous solutions and suspensions propylene glycol, polyethylene glycol, vegetable oil such as olive oils, injectable esters such as ethyl oleate, etc. can be used.
- suppository base For suppository base, witepsol, macrogol, tween 61, cacao butter, laurinum, glycerogelatin, etc. can be used.
- buffering agents such as phosphoric acid, citric acid, tartaric acid, malic acid and succinic acid, and pH adjusters such as hydrochloric acid, sulfuric acid, sodium hydroxide, potassium hydroxide can be also used.
- the dose of at least one of MA, MMA and SMA vary depending on age, sex or body weight of a patient, a typical dose is in the range of 0.01 to 100 mg/kg per day which can be administered once or in divided unit dosage.
- the dose of at least one of MA, MMA and SMA may vary depending on administration route, degree of symptoms, sex, body weight, age, etc. Accordingly, the above dose should not limit the scope of the present invention.
- the pharmaceutical composition of the present invention can be administered to mammals including rats, mice, cattle, humans, etc. Every administration route may be expected—for example, oral, rectal or intravenous, muscular, subcutaneous, intrauterine or intracerebroventricular injection may be used.
- Fertile eggs were obtained at Baekja Korean native chicken (Cheongsong, Korea).
- 2-Pyridine carboxaldehyde, 2-acetylfuran and cortisone acetate were obtained at Aldrich Chemical Co. (St. Louis, Mo., USA), VEGF and IL-8 at R&D Systems (Minneapolis, Minn., USA), TNF- ⁇ at Invitrogen Life Tech., Whatman filter disc at Whatman (UK), and batimastat at Tocris Bioscience (Ballwin, Mo., USA).
- MA, MMA and SMA were obtained by the preparation method disclosed in the patent application (PCT/KR2010/003239) owned by the present inventors.
- chorioallantoic membrane (CAM) analysis was carried out (Nguyen M. et al., Microvascular Res., 47, pp. 31-40, 1994). 6 ⁇ 1 fertile eggs were used per group.
- Fertile chicken eggs were cultured while maintaining the temperature of 37° C. and the relative humidity of 55%.
- a first small hole was made in the air sac part with a hypodermic needle (Green Cross Medical Corporation, Korea), and a second hole was made in the plat part of the fertile eggs to make a window.
- the CAM was separated from the eggshell by expelling the air through the first hole in the air sac, and then the part was cut with a grinding wheel (Multipro 395JA, Dremel, Mexico) to make a window.
- a grinding wheel Multipro 395JA, Dremel, Mexico
- a Whatman filter disc #1 (Whatman, USA) was treated with 3 mg/ml of cortisone acetate and dried. The filter disc was treated with 10 ⁇ l of VEGF, TNF- ⁇ or IL-8 (20 ng/CAM).
- the filter disc was put on blood vessel, and then treated with various concentrations of MA, MMA or SMA which was dissolved in DMSO and diluted with PBS.
- CAM part with the filter disc was separated and washed with phosphate buffer solution.
- the photographs were taken by using a stereomicroscope (Leica, Wetzlar, Germany) and Image-Pro Plus software (Media Cybernetics; Silver Spring, Md., USA) to determine the number of bleed vessel branches and to analyze the data.
- FIGS. 1 , 2 and 3 are photographs of the new blood vessels observed in each group and graphs representing the determined number of blood vessel branches in each group.
- FIGS. 1 a and 1 b representing the results of each test group treated with PBS, VEGF alone or VEGF and the macrolactin compounds in various concentrations
- MA, MMA and SMA strongly suppressed neovascular formation caused by VEGF.
- SMA suppressed neovascular formation in a dose-dependent way.
- FIGS. 2 a and 2 b representing the results of each test group treated with PBS, TNF- ⁇ alone or TNF- ⁇ and the macrolactin compounds in various concentrations, MA and SMA strongly suppressed neovascular formation caused by TNF- ⁇ . Especially, SMA strongly suppressed neovascular formation such that the number of blood vessel branches of the group treated with SMA in 20 ⁇ g/CAM was similar to the control group.
- FIGS. 3 a and 3 b representing the results of each test group treated with PBS, IL-8 alone or IL-8 and the macrolactin compounds in various concentrations
- MA and SMA strongly suppressed neovascular formation caused by IL-8.
- SMA strongly suppressed neovascular formation such that the number of blood vessel branches of the group treated with SMA in 20 ⁇ g/CAM was similar to the control group.
- neovascular formation caused by angiogenic inducers such as VEGF, TNF- ⁇ or IL-8 decreased significantly by treatment of the macrolactin compounds of the present invention.
- Human fibrosarcoma cells (HT-1080) were cultured in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PS) under the condition of 37° C. and 5% CO 2 . When the cells grew to fill 80% or more of the culture flask, they were subcultured at a ratio of 1:3 and used in this test.
- FBS fetal bovine serum
- PS penicillin/streptomycin
- an infiltration test of fibrosarcoma cells was carried out by using a 24-well transwell attached with a polycarbonate filter of 8 mm pore size. Firstly, the bottom side of the filter was coated with Collagen Type I (0.5 mg/ml), and then the upper side of the filter was coated with Matrigel (1.5 mg/ml). After coating, the lower part of the insert was filled with a medium containing 5% FBS, and the upper part was filled with serum-free medium human fibrosarcoma cells (HT-1080) which were incubated for 18 hours in a cell incubator.
- Collagen Type I 0.5 mg/ml
- Matrigel 1.5 mg/ml
- the human fibrosarcoma cells infiltrated into the bottom side of the filter were fixed with methanol and then dyed with hematoxylin and eosin.
- the infiltrated cells were observed under a microscope, and 3 parts were randomly selected from each filter to take photographs and determine the number of cells (Kim, M. S. et al., Cancer Res., 63, pp. 5454-5461, 2003; Park, B. C. et al., Eur. J. Pharm., 567, pp. 193-197, 2007).
- batimastat an inhibitor of matrix metalloproteinases (hereinafter, MMP), which is essential in metastasis of cancer, was used in a control group for the comparison of the suppressive effect of the macrolactin compounds on metastasis of cancer.
- MMP matrix metalloproteinases
- the infiltration of fibrosarcoma cells induced by 5% FBS increased, while in the control group treated with MMP inhibitor, batimastat 5 ⁇ M, the infiltration was significantly suppressed.
- MA and SMA suppressed metastasis of fibrosarcoma cells with infiltration induced by 5% FBS in a dose-dependent way.
- SMA 1 ⁇ M showed significant suppressive effect on the metastasis
- SMA 5 ⁇ M showed superior suppressive effect on the metastasis comparable to that of batimastat.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100068886 | 2010-07-16 | ||
PCT/KR2011/001228 WO2012008674A1 (fr) | 2010-07-16 | 2011-02-23 | Composition anti-angiogénique contenant de la macrolactine a et un dérivé associé en tant qu'ingrédients actifs |
JPI0-2010-0068886 | 2012-01-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/001228 A-371-Of-International WO2012008674A1 (fr) | 2010-07-16 | 2011-02-23 | Composition anti-angiogénique contenant de la macrolactine a et un dérivé associé en tant qu'ingrédients actifs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/941,932 Continuation US8940788B2 (en) | 2010-07-16 | 2013-07-15 | Anti-angiogenic composition containing macrolactin A and a derivative thereof as active ingredients |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130109745A1 true US20130109745A1 (en) | 2013-05-02 |
Family
ID=45469646
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/809,752 Abandoned US20130109745A1 (en) | 2010-07-16 | 2011-02-23 | Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients |
US13/941,932 Expired - Fee Related US8940788B2 (en) | 2010-07-16 | 2013-07-15 | Anti-angiogenic composition containing macrolactin A and a derivative thereof as active ingredients |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/941,932 Expired - Fee Related US8940788B2 (en) | 2010-07-16 | 2013-07-15 | Anti-angiogenic composition containing macrolactin A and a derivative thereof as active ingredients |
Country Status (7)
Country | Link |
---|---|
US (2) | US20130109745A1 (fr) |
EP (1) | EP2594268B1 (fr) |
JP (1) | JP5728085B2 (fr) |
KR (1) | KR101271593B1 (fr) |
CN (1) | CN103002892B (fr) |
CA (1) | CA2803999C (fr) |
WO (1) | WO2012008674A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10220021B2 (en) | 2014-09-09 | 2019-03-05 | Arturo Solis Herrera | Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102094255B1 (ko) | 2017-09-27 | 2020-03-30 | 한양대학교 산학협력단 | 종양 표적 치료용 락토페린-글리시리진 컨쥬게이트 |
CN110051680B (zh) * | 2018-01-19 | 2022-02-18 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用 |
JP7152052B2 (ja) | 2018-01-19 | 2022-10-12 | 沈陽福洋医薬科技有限公司 | カリマイシン又はその活性成分の用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080039407A1 (en) * | 2004-09-21 | 2008-02-14 | Timmis Kenneth N | Antibiotic and Method of Production Thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100764667B1 (ko) * | 2006-05-03 | 2007-10-08 | 한국생명공학연구원 | 펩타이드 디포밀레이즈 저해 및 항균활성을 갖는 신규이소마크로락틴 화합물 |
KR100895908B1 (ko) * | 2007-03-16 | 2009-05-04 | 일동제약주식회사 | 바실러스 폴리퍼멘티쿠스 케이제이에스-2 균주가 생산하는항균물질 마크로락틴 에이 |
JP2010011429A (ja) | 2008-06-30 | 2010-01-14 | Canon Inc | 画像処理装置及び画像処理装置の制御方法 |
KR101070324B1 (ko) * | 2009-05-22 | 2011-10-06 | 대우제약 주식회사 | 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항염제 조성물 |
-
2011
- 2011-02-14 KR KR1020110012707A patent/KR101271593B1/ko active IP Right Grant
- 2011-02-23 JP JP2013519563A patent/JP5728085B2/ja not_active Expired - Fee Related
- 2011-02-23 US US13/809,752 patent/US20130109745A1/en not_active Abandoned
- 2011-02-23 CN CN201180035102.1A patent/CN103002892B/zh not_active Expired - Fee Related
- 2011-02-23 WO PCT/KR2011/001228 patent/WO2012008674A1/fr active Application Filing
- 2011-02-23 EP EP11806959.0A patent/EP2594268B1/fr not_active Not-in-force
- 2011-02-23 CA CA2803999A patent/CA2803999C/fr not_active Expired - Fee Related
-
2013
- 2013-07-15 US US13/941,932 patent/US8940788B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080039407A1 (en) * | 2004-09-21 | 2008-02-14 | Timmis Kenneth N | Antibiotic and Method of Production Thereof |
Non-Patent Citations (1)
Title |
---|
by Jha et al. Biomedical Compounds from Marine Organisms, 2004, Marine Drugs, 2, page 126, lines 3-4. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10220021B2 (en) | 2014-09-09 | 2019-03-05 | Arturo Solis Herrera | Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives |
Also Published As
Publication number | Publication date |
---|---|
US20130303600A1 (en) | 2013-11-14 |
EP2594268A1 (fr) | 2013-05-22 |
CN103002892B (zh) | 2016-03-30 |
EP2594268B1 (fr) | 2016-10-19 |
KR101271593B1 (ko) | 2013-06-11 |
WO2012008674A1 (fr) | 2012-01-19 |
CA2803999A1 (fr) | 2012-01-19 |
CA2803999C (fr) | 2015-11-24 |
KR20120008429A (ko) | 2012-01-30 |
JP5728085B2 (ja) | 2015-06-03 |
JP2013531032A (ja) | 2013-08-01 |
CN103002892A (zh) | 2013-03-27 |
EP2594268A4 (fr) | 2013-12-18 |
US8940788B2 (en) | 2015-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8940788B2 (en) | Anti-angiogenic composition containing macrolactin A and a derivative thereof as active ingredients | |
US7482027B2 (en) | Composition for the prevention or treatment of diseases associated with angiogenesis | |
CN114617914A (zh) | 一种防治神经退行性疾病的新型药物 | |
US9505757B2 (en) | Pharmaceutical composition comprising bicyclic pyridinol derivatives for preventing or treating diseases caused by angiogenesis | |
EP2808025A1 (fr) | Composition pharmaceutique et produit cosmétique quasi-médicamenteux utilisant celle-ci | |
KR102076137B1 (ko) | 수축력 저하 수반성 배뇨근 과활동 개선제 | |
KR102279105B1 (ko) | 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물 | |
KR20220073985A (ko) | 모노메틸푸마레이트를 유효성분으로 포함하는 장기 섬유증의 예방 또는 치료용 약학적 조성물 | |
WO2019114676A1 (fr) | Nouvelle utilisation médicale d'extrait de feuilles de kaki et d'une préparation d'extrait de feuilles de kaki | |
KR20130065899A (ko) | 티오아데노신 유도체 및 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 퇴행성 뇌질환 치료 및 예방용 조성물 | |
KR102532055B1 (ko) | 다이하이드로퓨란-2-온 유도체를 포함하는 염증성 질환 치료용 조성물 | |
CN117298086B (zh) | 索法酮在制备预防和/或治疗nlrp3炎性小体介导的疾病的药物中的应用 | |
US20230210828A1 (en) | Therapeutic agent for vascular disorder | |
KR102153338B1 (ko) | 카나리움 서부라텀(Canarium subulatum) 추출물을 유효성분으로 포함하는, 염증성 질환 예방 또는 치료용 약학적 조성물 | |
CN112168831B (zh) | 一个雷公藤内酯醇衍生物在防治炎症性肠病中的用途 | |
US20230263767A1 (en) | Composition for preventing, alleviating, or treating inflammatory disease containing isookanin or salt thereof as active ingredient | |
CN118680913A (zh) | Isrib在制备治疗血管衰老疾病或动脉粥样硬化的药物中的应用 | |
KR20220170522A (ko) | 로리올라이드를 유효성분으로 포함하는 항염증용 조성물 | |
KR20220025976A (ko) | 신규한 화합물을 유효성분으로 포함하는 심근경색 후 심부전 예방 또는 치료용 조성물 및 이의 용도 | |
CN118139618A (zh) | 包含异樱花素或其药学上可接受的盐作为活性成分的用于预防或治疗肝硬化的药物组合物 | |
CN117298095A (zh) | 野马追倍半萜内酯类化合物在制备用于治疗/预防nlrp3炎性小体介导疾病药物的应用 | |
KR20230168677A (ko) | 레반 나노입자를 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
CN113181162A (zh) | 一种靶向Bach2的小分子激动剂杨梅酮的应用 | |
TWI386218B (zh) | The use of the king of the line of ethanol extracted products to treat diabetic nephropathy caused by renal fibrosis | |
KR20120047345A (ko) | Il-6 활성 억제 작용을 갖는 화합물 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 il-6로 매개되는 질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DAEWOO PHARMACEUTICAL IND. CO., LTD., KOREA, REPUB Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JI, YOUNG-HOON;KIM, DONG-HEE;KIM, JUNG-AE;AND OTHERS;SIGNING DATES FROM 20121119 TO 20121120;REEL/FRAME:029614/0733 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |